- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
NEW ORLEANS, May 26, 2026 /PRNewswire/ -- 28bio today announced the launch of the CNS-3D Induced Alzheimer's Model, a brain organoid assay enabling researchers to evaluate whether therapeutic ...
This episode of the Pharmaron DMPK Insights Podcast Series sees Scott Summerfield (Senior Director and Head of Pharmaceutical Metabolism at Pharmaron) and Professor Elizabeth de Lange Professor in ...
The MarketWatch News Department was not involved in the creation of this content. -- CANDID-CNS(TM) is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small ...
Founding CEO of Allele Biotech and President of the Scintillon Institute, he is an RNA molecular biologist advancing mRNA-based reprogramming and iPSC engineering. He develops high-potency transient ...
Insilicotrials Technologies SpA has entered into a collaborative partnership with Axoltis Pharma SA in the field of central nervous system (CNS) diseases, with the aim of optimizing the clinical ...
Expands suite of capabilities to model human pathogenesis and functional recovery for neurodegenerative diseases NEW ORLEANS, May 26, 2026 /PRNewswire/ -- 28bio today announced the launch of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results